Nuclera
On-demand gene to protein synthesis
- 101-200 employees
- Healthcare
- B2B
- Biology
- Histon, UK
Jump to section
Company mission
To solve biological inaccessibility.
Our take
Founded out of research at the University of Cambridge, Nuclera is a biotech company developing protein-printing technologies to make proteins more accessible to everyone. In doing so, the bioprinter company enables life science researchers to accelerate breakthrough improvements in human health due to better access to biomolecules.
The company is somewhat revolutionary seeing as developing proteins has long been a time-consuming and complicated process. Rather than taking weeks, months, or years, Nuclera’s eProtein desktop bioprinting technology does so in hours.
Trust in the product is marked by substantial funding between 2018 and 2022, which is being invested into accelerating the development and commercialization of the eProtein desktop bioprinter.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Generous Holidays - Everyone in the UK and the USA enjoys a 25 days annual leave per year
- Stock Option - Generous stock options in addition to our competitive salary
- Private Health Insurance - Everyone at Nuclera can enjoy a private health insurance scheme
- Refreshment - Fresh fruit, tea, coffee and snacks in the office
- Life Insurance - We offer up to 4x your salary in your life insurance package
- Pension Scheme - Whether it's UK pension or 401(k) in the USA, we have you covered
Funding (last 2 of 8 rounds)
Oct 2024
$75m
SERIES C
Jun 2024
$1.5m
GRANT
Total funding: $145m
This company has top investors
Leadership
Gordon McInroy
(CTO)Previously acted as a Postdoctoral Research Associate for the University of Cambridge, before founding and acting as CSO for Nuclera.
Jiahao Huang
(CFO)Previously acted as a Research Analyst for Strategic Partnerships Office for the University of Cambridge.
Michael Chen
(CEO)Previously studied at the University of Cambridge, National Institutes of Health, and Georgia Institute of Technology.